| 0.731 -0.02 (-2.61%) | 07-17 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 1.01 | 1-year : | 1.16 |
| Resists | First : | 0.87 | Second : | 0.99 |
| Pivot price | 0.77 |
|||
| Supports | First : | 0.67 | Second : | 0.55 |
| MAs | MA(5) : | 0.76 |
MA(20) : | 0.77 |
| MA(100) : | 0.8 |
MA(250) : | 1.12 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 26.3 |
D(3) : | 29.9 |
| RSI | RSI(14): 43.4 |
|||
| 52-week | High : | 2.18 | Low : | 0.5 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ TELA ] has closed above bottom band by 29.3%. Bollinger Bands are 19.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 0.82 - 0.83 | 0.83 - 0.83 |
| Low: | 0.72 - 0.72 | 0.72 - 0.73 |
| Close: | 0.72 - 0.73 | 0.73 - 0.74 |
TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s anatomy. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was incorporated in 2012 and is headquartered in Malvern, Pennsylvania.
Fri, 17 Jul 2026
Form 4 Tela Bio Inc For: 17 July By Investing.com - Investing.com Canada
Fri, 17 Jul 2026
TELA Bio (TELA) awards director 6,227 fully vested compensation shares - Stock Titan
Fri, 17 Jul 2026
TELA Bio (TELA) director granted 20,930 fully vested shares - Stock Titan
Thu, 25 Jun 2026
TELA Forecast — Price Target — Prediction for 2027 - TradingView
Fri, 15 May 2026
Earnings Release: Here's Why Analysts Cut Their TELA Bio, Inc. (NASDAQ:TELA) Price Target To US$2.25 - Yahoo Finance
Wed, 13 May 2026
Becton Hernia Mesh Antitrust Case Survives Dismissal - Law360
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 45 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 7.6 (%) |
| Held by Institutions | 68.9 (%) |
| Shares Short | 466 (K) |
| Shares Short P.Month | 748 (K) |
| EPS | -0.78 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -0.12 |
| Profit Margin | -49.3 % |
| Operating Margin | -55.3 % |
| Return on Assets (ttm) | -28.8 % |
| Return on Equity (ttm) | -616.7 % |
| Qtrly Rev. Growth | 2.9 % |
| Gross Profit (p.s.) | 1.22 |
| Sales Per Share | 1.8 |
| EBITDA (p.s.) | -0.74 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | -0.94 |
| PEG Ratio | 0 |
| Price to Book value | -6.1 |
| Price to Sales | 0.4 |
| Price to Cash Flow | -1.11 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|